Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2005;111:2219-2226
Published online before print April 25, 2005, doi: 10.1161/01.CIR.0000163544.17221.BE
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
111/17/2219    most recent
01.CIR.0000163544.17221.BEv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, Y.-X.
Right arrow Articles by Light, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, Y.-X.
Right arrow Articles by Light, D. R.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Animal models of human disease
Right arrow Apoptosis
Right arrow Mechanism of atherosclerosis/growth factors
Right arrow Other Vascular biology

(Circulation. 2005;111:2219-2226.)
© 2005 American Heart Association, Inc.


Vascular Medicine

Fasudil, a Rho-Kinase Inhibitor, Attenuates Angiotensin II–Induced Abdominal Aortic Aneurysm in Apolipoprotein E–Deficient Mice by Inhibiting Apoptosis and Proteolysis

Yi-Xin Wang, MD; Baby Martin-McNulty, BS; Valdeci da Cunha, PhD; Jon Vincelette, BS; Xiangru Lu, MD; Qingping Feng, MD, PhD; Meredith Halks-Miller, MD; Mithra Mahmoudi, MS; Miriam Schroeder, BS; Babu Subramanyam, PhD; Jih-Lie Tseng, PhD; Gary D. Deng, MD, PhD; Sabine Schirm, PhD; Anthony Johns, PhD; Katalin Kauser, MD, PhD; William P. Dole, MD; David R. Light, PhD

From Berlex Biosciences, Richmond, Calif (Y.-X.W., B.M.-M., V.d.C., J.V., M.H.-M., M.M., M.S., B.S., J.-L.T., G.D.D., S.S., A.J., K.K., W.P.D., D.R.L.), and the University of Western Ontario, London, Ontario, Canada (X.L., Q.F.).

Correspondence to Yi-Xin (Jim) Wang, Berlex Biosciences, 2600 Hilltop Dr, Richmond, CA 94804. E-mail jim_wang{at}berlex.com

Received October 11, 2004; revision received December 2, 2004; accepted December 8, 2004.

Background— Angiotensin II (Ang II) accelerates atherosclerosis and induces abdominal aortic aneurysm (AAA) in an experimental mouse model. Agonism of a G protein–coupled receptor by Ang II activates Rho-kinase and other signaling pathways and results in activation of proteolysis and apoptosis. Enhanced proteolysis and smooth muscle cell apoptosis are important mechanisms associated with AAA. In this study, we tested the hypothesis that fasudil, a Rho-kinase inhibitor, could attenuate Ang II–induced AAA formation by inhibiting vascular wall apoptosis and extracellular matrix proteolysis.

Methods and Results— Six-month-old apolipoprotein E–deficient mice were infused with Ang II (1.44 mg · kg–1 · d–1) for 1 month. Animals were randomly assigned to treatment with fasudil (136 or 213 mg · kg–1 · d–1 in drinking water) or tap water. Ang II infusion induced AAA formation in 75% of the mice, which was accompanied by an increase in proteolysis detected by zymographic analysis and quantified by active matrix metalloproteinase-2 activity, as well as apoptosis detected by terminal deoxynucleotidyl transferase–mediated dUTP nick-end labeling and quantified by both caspase-3 activity and histone-associated DNA fragmentation. The level of DNA fragmentation in the suprarenal aorta correlated with AAA diameter. Ang II also increased atherosclerotic lesion area and blood pressure. Fasudil treatment resulted in a dose-dependent reduction in both the incidence and severity of AAA. At the higher dose, fasudil decreased AAA by 45% while significantly inhibiting both apoptosis and proteolysis, without affecting atherosclerosis or blood pressure.

Conclusions— These data demonstrate that inhibition of Rho-kinase by fasudil attenuated Ang II–induced AAA through inhibition of both apoptosis and proteolysis pathways.


Key Words: angiotensin II • aortic aneurysm, abdominal • mice, knockout • apoptosis • metalloproteinases




This article has been cited by other articles:


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
H. Ikeda, Y. Kume, K. Tejima, T. Tomiya, T. Nishikawa, N. Watanabe, N. Ohtomo, M. Arai, C. Arai, M. Omata, et al.
Rho-kinase inhibitor prevents hepatocyte damage in acute liver injury induced by carbon tetrachloride in rats
Am J Physiol Gastrointest Liver Physiol, October 1, 2007; 293(4): G911 - G917.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
P. Rivera, M. P. Ocaranza, S. Lavandero, and J. E. Jalil
Rho Kinase Activation and Gene Expression Related to Vascular Remodeling in Normotensive Rats With High Angiotensin I Converting Enzyme Levels
Hypertension, October 1, 2007; 50(4): 792 - 798.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. Golledge, J. Muller, A. Daugherty, and P. Norman
Abdominal Aortic Aneurysm: Pathogenesis and Implications for Management
Arterioscler. Thromb. Vasc. Biol., December 1, 2006; 26(12): 2605 - 2613.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
H. Ohtsu, H. Suzuki, H. Nakashima, S. Dhobale, G. D. Frank, E. D. Motley, and S. Eguchi
Angiotensin II Signal Transduction Through Small GTP-Binding Proteins: Mechanism and Significance in Vascular Smooth Muscle Cells
Hypertension, October 1, 2006; 48(4): 534 - 540.
[Full Text] [PDF]


Home page
Circ. Res.Home page
G. Loirand, P. Guerin, and P. Pacaud
Rho Kinases in Cardiovascular Physiology and Pathophysiology
Circ. Res., February 17, 2006; 98(3): 322 - 334.
[Abstract] [Full Text] [PDF]